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Summary. This review summarizes the steps that led
to the development of desmopressin as a hemostatic
agent. This drug has broadened the panel of
pharmacological agents that can be used to treat or
prevent bleeding in patients with mild hemophilia
and von Willebrand disease.
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Pharmacological compounds that potentiate the
haemostatic mechanisms have attracted the interest
of many scientists for more than two centuries. The
first relevant observation in this field was made in the
middle of the eighteenth century by William Hewson
[1], who noticed an acceleration of blood clotting
after acute haemorrhage. This observation was
revisited first in 1903 by Vosburgh and Richards
[2], who reported a shortening of the clotting time in
dogs after administration of adrenaline. It was
followed in 1914 by the famous American physiol-
ogist Cannon et al. [3–5], who reported several
detailed investigations on the effect on blood clotting
of adrenaline and of various procedures (such as
pain, emotional excitement, haemorrhage and
splanchnic stimulation) that release adrenaline in
dogs. The first real clue in understanding the mech-
anism underlying the acceleration of blood clotting
induced by adrenaline was the discovery by Ingram
[6] that the injection of adrenaline into healthy
humans is followed by a short-term rise in the
coagulant activity of factor VIII (FVIII:C), the factor
deficient in classic haemophilia. Interestingly, adren-
aline also raises FVIII:C in FVIII:C-deficient patients
with mild haemophilia [6] and von Willebrand
disease (VWD) [7]. Strenuous physical exercise
produces a similar rise [8], both in normal persons
and in mild haemophiliacs, and this rise is mediated
by the release of endogenous adrenaline.
These observations stimulated further research,
because it was obvious that pharmacologic com-
pounds that circumvented the need for strenuous
exercise and lacked the side-effects of adrenaline
could be potentially useful to raise FVIII:C in the
management of haemophilia and VWD. In particular,
this therapy might decrease the need for the use of
blood products, which transmitted hepatitis and
other infections and were not largely available in
the 1960s when these studies first appeared. Hence,
a potential alternative to plasma-derived FVIII:C
appeared at that time a substantial advance for the
management of haemophilia and VWD. Other phar-
macological compounds, such as vasopressin and its
derivates and insulin, were subsequently found to
induce a short-term rise of FVIII:C [9], but again
severe side-effects made their clinical use unrealistic.
An important step forward was made in the early
1970s, with the independent observations by Cash
et al. [10] and Mannucci et al. [11] that 1-deamino-
8-d-arginine vasopressin (DDAVP, desmopressin), a
synthetic analogue of the antidiuretic hormone
l-arginine vasopressin (AVP), raises plasma FVIII:C
levels when infused into healthy volunteers. The
effects of desmopressin on the haemostatic system
are not restricted to FVIII:C, because the compound,
like other drugs that augment FVIII:C, also raises the
plasma levels of the von Willebrand factor (VWF)
[12] and plasminogen activator [13]. Unlike the
natural antidiuretic hormone and the majority of its
synthetic analogues, desmopressin has very little
effect on the V1 vasopressin receptors of the smooth
muscle cells, the ratio of its antidiuretic (mediated by
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V2 receptors) to its pressor V1 activity being
approximately 2000–3000 times greater than that
of the parent hormone [14]. Accordingly, it produces
little or no constriction of the vessel and smooth
muscle [14], as these effects are related to the
stimulation of V1 receptors. These differences are
the result of molecular manipulations of vasopressin
involving deamination of homocysteine at position 1,
which results in a more prolonged duration of action
of the antidiuretic defect (2–6 h for vasopressin, 6–
24 h for desmopressin), and substitution of the
d-isomer of arginine for l-arginine at position 8,
which leads to a diminished pressor activity [14].
In 1977, Mannucci et al. [15] were the first to use
desmopressin for the prevention of bleeding during
dental extraction and then during major surgical
procedures carried out in 25 patients with moderate
or mild haemophilia or VWD. Surgical procedures
were safely performed without the administration of
blood products, showing that autologous FVIII:C
and VWF induced by administration of desmopressin
in plasma could effectively replace homologous
FVIII:C and VWF contained in blood products. The
only side-effects were mild facial flushing, a 10–20%
increase in pulse rate and minor falls in systolic and
diastolic blood pressure. These results were subse-
quently confirmed by several investigators, and
desmopressin has now an established place in the
management of patients with mild haemophilia A
and type 1 VWD [16].
Subsequently, its use was proposed with increasing
frequency in the management of haemostatic disor-
ders other than haemophilia and VWD, suggesting
that the clinical indications for the compound might
be even wider than hitherto appreciated (Fig. 1). In
1986, Salzman et al. [17] showed that desmopressin
reduced by approximately 30% blood loss and
transfusion requirements during operations of car-
diac surgery. Subsequent attempts to reproduce these
findings gave varied results, but the majority of them
failed to confirm the marked benefits originally
found [18–20]. A few meta-analyses indicated that
although desmopressin does indeed reduce perioper-
ative blood loss, the effect is too small to influence
other more relevant clinical outcomes such as the
need for transfusion and reoperation [21–23]. Des-
mopressin did not reduce blood loss nor transfusion
requirements during elective partial hepatectomy,
another operation often associated with major blood
loss [24]. The initial finding that desmopressin
reduced blood loss associated with posterior spinal
surgery for idiopathic scoliosis [25] was not con-
firmed by subsequent studies [26–28]. The use of this
drug to shorten the prolonged bleeding time in
patients with uraemia [29] is no longer necessary
after the widespread use of recombinant erythropoi-
etin which makes this haemostasis abnormality much
less frequent [30]. The use of desmopressin in some
patients who bleed as a consequence of inherited and
acquired defects of platelet function may be consid-
ered, although these indications are not supported by
sound clinical evidence on relevant endpoints [31].
The most common adverse effects of desmopressin
are usually mild (facial flushing, transient hyponat-
remia), although arterial thrombotic events have
been reported [31].
The development and clinical use of desmopressin
in clinical medicine is summarized in Fig. 1. In all,
the availability of desmopressin has broadened the
panel of pharmacological agents that can be
Fig. 1. Chronological development of
clinical indications for desmopressin
(DDAVP).
2 P. M. MANNUCCI
 2008 The Author
Haemophilia (2008), 14 (Suppl. 1), 1–4 Journal compilation  2008 Blackwell Publishing Ltd
employed to treat acute haemorrhage or to prevent
bleeding in patients with mild haemophilia and
VWD. This drug is not a universal panacea good
for all purposes but is relatively inexpensive and has
little side-effects. We could demonstrate that its
early use in Italy at the onset of the outbreak
of acquired immunodeficiency syndrome (AIDS)
reduced the number of patients with mild haemo-
philia A who became human immunodeficiency
virus (HIV)-infected, in comparison with Italian
patients with haemophilia B who could not use
desmopressin because it does not raise factor IX
[32]. One has to be cognizant that the use of any
drug that potentiates haemostasis cannot be without
the risk of thrombosis, particularly when they are
used in elderly people and in those with other risk
factors for thrombosis.
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